Abemaciclib is a drug for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. It is also being tested in other cancers including myeloma.
| SparkCures ID | 325 |
|---|---|
| Developed By | Eli Lilly and Company |
| Brand Name | Verzenio® |
| Generic Name | Abemaciclib |
| Treatment Classifications |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.